UPDATE: ISI Group Cuts PT to $39 on Charles River Laboratories Following Negative Guidance
ISI Group reiterated its Underweight rating on Charles River Laboratories (NYSE: CRL) and lowered its price target from $40.50 to $39.
ISI Group commented, "As a result of today's 2013 guidance announcement, we are lowering CRL's FY13 EPS from $3.10 to $3.00 and FY14 EPS from $3.45 to $3.25. These EPS changes stem from lower operating margin expectations due to the aforementioned investment headwinds. Despite the improved revenue outlook, limited visibility across the business (ex strategic deals) and a challenged OM outlook will limit P/E expansion, and in turn, cap shares in the upper $30s."
Charles River Laboratories closed at $36.55 on Tuesday.
Latest Ratings for CRL
|Jul 2015||Morgan Stanley||Maintains||Equal-weight|
|Jul 2015||Bank of America||Upgrades||Neutral||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.